Ennaid Therapeutics LLC: Company Profile

Background

Ennaid Therapeutics LLC is a global biopharmaceutical company headquartered in Alpharetta, Georgia, USA, with subsidiaries in Australia, the United Kingdom, and India. Established in 2012, the company specializes in developing antiviral therapeutics targeting diseases within the Flaviviridae and Coronaviridae families, including Zika virus, Dengue virus, and SARS-CoV-2. Ennaid leverages advanced artificial intelligence (AI)-based drug discovery platforms to identify and develop broad-spectrum antiviral drugs. The company's mission is to address global health challenges by providing innovative and effective treatments for infectious diseases. Ennaid's vision is to become a leader in antiviral drug development, improving public health through scientific innovation.

Key Strategic Focus

Ennaid's strategic focus centers on the rapid development of antiviral therapeutics for infectious diseases, particularly those caused by mosquito-borne viruses and coronaviruses. The company's core objectives include:

Rapid Drug Development: Accelerating the creation of effective antiviral treatments to address urgent public health needs.

AI-Driven Drug Discovery: Utilizing AI technologies to identify potential antiviral compounds efficiently.

Global Health Impact: Developing therapies that can be distributed worldwide to combat infectious diseases.

Ennaid specializes in antiviral drug development, focusing on diseases such as Zika virus, Dengue virus, and COVID-19. The company employs AI-based drug discovery platforms to identify and develop therapeutic candidates. Ennaid's primary markets include regions affected by mosquito-borne diseases and global markets impacted by COVID-19.

Financials and Funding

Specific details regarding Ennaid Therapeutics' total funds raised, recent funding rounds, and notable investors are not publicly disclosed. The company has engaged in strategic partnerships to advance its drug development programs. For instance, in May 2020, Ennaid collaborated with Catalent to develop an oral antiviral treatment for COVID-19, with Catalent's San Diego facility manufacturing formulations of Ennaid's ENU200 program. Additionally, in June 2021, Ennaid entered into an exclusive partnership with Strides Pharma Science Limited to produce an oral medication for treating mild, moderate, and asymptomatic cases of COVID-19. These collaborations indicate a strategic approach to funding and resource allocation to support Ennaid's therapeutic development initiatives.

Pipeline Development

Ennaid Therapeutics has developed a robust pipeline of antiviral therapeutics targeting various infectious diseases:

COVID-19 Therapeutics: The company has identified multiple compounds with antiviral activity against SARS-CoV-2, including ENU200, a repurposed oral antiviral drug. In May 2020, Ennaid collaborated with Catalent to develop a powder-in-capsule formulation of ENU200. In June 2021, Ennaid partnered with Strides Pharma Science Limited to produce an oral medication for treating mild, moderate, and asymptomatic cases of COVID-19.

Mosquito-Borne Diseases: Ennaid has developed therapeutics targeting Zika virus and Dengue virus, utilizing a proprietary technology that shows over 99% inhibition of flavivirus infectivity.

Oncology: The company has a patented, repurposed drug that may treat advanced-stage colorectal cancer.

Digital Health: Ennaid is developing digital health products, including a software-based diagnostic for traumatic brain injuries and a clinical trial reporting software with telemedicine features.

Technological Platform and Innovation

Ennaid Therapeutics distinguishes itself through the following technological platforms and innovations:

Proprietary Technologies: The company has developed peptide fusion inhibitors that show significant inhibition against flavivirus infectivity, including Zika and Dengue viruses.

Scientific Methods: Ennaid employs AI-based drug discovery platforms to identify potential antiviral compounds efficiently.

Digital Health Capabilities: The company is developing digital health products, such as the ROME (Repeatable Objective Measure of Eyetrack) diagnostic, which can diagnose and measure traumatic brain injuries over time.

Leadership Team

Ennaid Therapeutics is led by a team of experienced professionals:

Darnisha Harrison, President & CEO: A microbiologist and chemist with over 20 years in business development and licensing in pharmaceutical R&D. She is a nationally recognized entrepreneur and has been featured in Newsweek magazine.

Scott Michael, Ph.D., Chief Scientific Officer: Co-inventor of Ennaid’s peptide technology, with nearly 30 years of experience in antiviral and vaccine research and development.

Janet VonKohn, Chief Global Strategist: With over 25 years as an entrepreneur and global strategist, she builds teams and commercial strategies to launch new drug products.

William Howe, Chief Operating Officer: Inventor of ROME, Ennaid’s digital health diagnostic for traumatic brain injuries, and founder of the Mosquito-Borne Research Foundation.

Chris Moreton, Ph.D., Head of Pharmaceutical Sciences: With over 30 years of experience in antiviral and vaccine research and development.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within Ennaid Therapeutics' leadership team.

Competitor Profile

Market Insights and Dynamics

The global antiviral therapeutics market is experiencing significant growth, driven by the increasing prevalence of infectious diseases and the need for effective treatments. The market is characterized by rapid innovation, with companies leveraging advanced technologies to develop novel antiviral drugs.

Competitor Analysis

Ennaid Therapeutics operates in a competitive landscape with several key players:

Catalent: A global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Catalent collaborated with Ennaid in May 2020 to develop an oral antiviral treatment for COVID-19.

Strides Pharma Science Limited: An India-based pharmaceutical company that partnered with Ennaid in June 2021 to produce an oral medication for treating mild, moderate, and asymptomatic cases of COVID-19.

Other Competitors: Companies such as Adimmune Corp, BioNet-Asia Co Ltd, and Zydus Lifesciences Ltd are also involved in developing antiviral therapeutics for diseases like Japanese Encephalitis.

Strategic Collaborations and Partnerships

Ennaid has formed strategic collaborations to enhance its drug development capabilities:

Catalent: Collaborated to develop an oral antiviral treatment for COVID-19.

Strides Pharma Science Limited: Entered into an exclusive partnership to produce an oral medication for treating mild, moderate, and asymptomatic cases of COVID-19.

Universidad Católica de Murcia (UCAM): Partnered to identify therapeutic targets for COVID-19 using AI drug discovery platforms.

Operational Insights

Ennaid's strategic collaborations with companies like Catalent and Strides Pharma Science Limited strengthen its market position by leveraging manufacturing expertise and expanding distribution capabilities. These partnerships enable Ennaid to accelerate the development and production of antiviral therapeutics, enhancing its competitive advantage in the global market.